Is Buying Biocept Incorporated (NASDAQ:BIOC) Here Good Idea?

May 19, 2017 - By Winifred Garcia

 Is Buying Biocept Incorporated (NASDAQ:BIOC) Here Good Idea?

The stock of Biocept Incorporated (NASDAQ:BIOC) registered a decrease of 1.6% in short interest. BIOC’s total short interest was 3.46 million shares in May as published by FINRA. Its down 1.6% from 3.51 million shares, reported previously. With 701,000 shares average volume, it will take short sellers 5 days to cover their BIOC’s short positions. The short interest to Biocept Incorporated’s float is 24.62%. It is 0.00% or $0 reaching $1.42 per share. It is down 6.00% since April 19, 2017 and is uptrending. It has by 0.00% the S&P500.

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The company has market cap of $38.31 million. The Firm develops and commercializes circulating tumor cell and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. It currently has negative earnings. The Company’s Target-Selector offering is based on an internally developed, microfluidics CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Biocept Inc (NASDAQ:BIOC) Ratings Coverage

Among 2 analysts covering Biocept Inc (NASDAQ:BIOC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biocept Inc had 2 analyst reports since August 19, 2015 according to SRatingsIntel. H.C. Wainwright initiated the stock with “Buy” rating in Wednesday, August 19 report. Roth Capital initiated Biocept Inc (NASDAQ:BIOC) rating on Monday, June 6. Roth Capital has “Buy” rating and $1.20 target.

More notable recent Biocept Inc (NASDAQ:BIOC) news were published by: Prnewswire.com which released: “Biocept’s Target Selector Platform Featured in Three Clinical Abstracts at the …” on May 18, 2017, also Prnewswire.com with their article: “Biocept Reports First Quarter 2017 Financial Results” published on May 11, 2017, Prnewswire.com published: “Biocept to Release First Quarter 2017 Financial Results and Host Investor …” on May 03, 2017. More interesting news about Biocept Inc (NASDAQ:BIOC) were released by: Prnewswire.com and their article: “Biocept Reports Fourth Quarter and Full Year 2016 Financial Results” published on March 07, 2017 as well as Prnewswire.com‘s news article titled: “Biocept Announces Pricing of $9.3 Million Financing” with publication date: March 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.